Selinexor, XPOVIO (Severe COVID )
Stage (next event)
Phase 2 (Data at ISIRV-AVG )
Catalyst Info & Data Links
TITLE: Selinexor, XPOVIO for Severe COVD-19 - Phase 2
ClinicalTrial.gov (NCT04349098): Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection (Coronavirus)
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
10-06-2020 Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19
08-04-2020 Interim Analysis & Q2 2020 Financial Results
06-2020: Corporate Presentation (slides 45-46)
08-2020: COVID Interim Analysis & Corporate Presentation (slides 45-47)
2020: A Case Report of a COVID-19 Patient Treated with the Selective Inhibitor of Nuclear Export (SINE) Drug, Selinexor. Ann Case Report, 14, 478.
MECHANISM OF ACTION/RATIONALE
Nuclear export inhibitor
Inhibits XPO1 (see slide 5), which is believed to impact tumor cells in 3 ways
1. Increases nuclear levels and activation of tumor suppressor proteins
2. Traps oncoprotein mRNA in the nucleus leading to reduced oncoprotein levels
3. Retains activated glucocorticoid receptor in the nucleus
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post